Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Robust in vitro assay for analyzing the neutralization activity of serum specimens against hepatitis B virus.

Zhang YL, Gao Y, Cao JL, Zhao JH, Zhang TY, Yang CL, Xiong HL, Wang YB, Ou SH, Cheng T, Chen CR, Yuan Q, Xia NS.

Emerg Microbes Infect. 2019;8(1):724-733. doi: 10.1080/22221751.2019.1619485.

2.

Emerging biomaterials for downstream manufacturing of therapeutic proteins.

Li Y, Stern D, Lock LL, Mills J, Ou SH, Morrow M, Xu X, Ghose S, Li ZJ, Cui H.

Acta Biomater. 2019 Sep 1;95:73-90. doi: 10.1016/j.actbio.2019.03.015. Epub 2019 Mar 9. Review.

PMID:
30862553
3.

Long-term HEV carriers without antibody seroconversion among eligible immunocompetent blood donors.

Wen GP, Chen CR, Song XY, Tang ZM, Ji WF, Wang SL, Zhang K, Zhang J, Ou SH, Zheng ZZ, Xia NS.

Emerg Microbes Infect. 2018 Jul 5;7(1):125. doi: 10.1038/s41426-018-0125-y.

4.

Diagnosis of immunomarkers in vivo via multiplexed surface enhanced Raman spectroscopy with gold nanostars.

Ou YC, Webb JA, O'Brien CM, Pence IJ, Lin EC, Paul EP, Cole D, Ou SH, Lapierre-Landry M, DeLapp RC, Lippmann ES, Mahadevan-Jansen A, Bardhan R.

Nanoscale. 2018 Jul 13;10(27):13092-13105. doi: 10.1039/c8nr01478g.

PMID:
29961778
5.

Bioinspired supramolecular engineering of self-assembling immunofibers for high affinity binding of immunoglobulin G.

Li Y, Lock LL, Wang Y, Ou SH, Stern D, Schön A, Freire E, Xu X, Ghose S, Li ZJ, Cui H.

Biomaterials. 2018 Sep;178:448-457. doi: 10.1016/j.biomaterials.2018.04.032. Epub 2018 Apr 16.

PMID:
29706234
6.

Molecularly imprinted electrochemical sensor, formed on Ag screen-printed electrodes, for the enantioselective recognition of d and l phenylalanine.

Ou SH, Pan LS, Jow JJ, Chen HR, Ling TR.

Biosens Bioelectron. 2018 May 15;105:143-150. doi: 10.1016/j.bios.2018.01.010. Epub 2018 Jan 6.

PMID:
29412938
7.

Conformation Preservation of α-Helical Peptides within Supramolecular Filamentous Assemblies.

Li Y, Wang Y, Ou SH, Lock LL, Xu X, Ghose S, Li ZJ, Cui H.

Biomacromolecules. 2017 Nov 13;18(11):3611-3620. doi: 10.1021/acs.biomac.7b00992. Epub 2017 Sep 27.

PMID:
28891286
8.

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.

Zhu V, Ou SH.

Expert Opin Drug Saf. 2017 Apr;16(4):509-514. doi: 10.1080/14740338.2017.1299706. Epub 2017 Mar 3. Review.

PMID:
28276856
9.

[Prevalence of Parvovirus B19 Infection in Chinese Xiamen Area Blood Donors].

Ou SH, Xie JZ, Zhang YL, Ni HY, Song XY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Oct;24(5):1572-1576. doi: 10.7534/j.issn.1009-2137.2016.05.052. Chinese.

PMID:
27784395
10.

[Prognostic analysis of acute-on-chronic liver failure after withdrawal of nucleos(t)ide analogues for antiviral treatment of chronic hepatitis B].

Ou SH, Chen YP, Jiang RL, Peng J.

Zhonghua Gan Zang Bing Za Zhi. 2016 Apr;24(4):252-7. doi: 10.3760/cma.j.issn.1007-3418.2016.04.003. Chinese.

PMID:
27470622
11.

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.

Schrock AB, Frampton GM, Suh J, Chalmers ZR, Rosenzweig M, Erlich RL, Halmos B, Goldman J, Forde P, Leuenberger K, Peled N, Kalemkerian GP, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.

J Thorac Oncol. 2016 Sep;11(9):1493-502. doi: 10.1016/j.jtho.2016.06.004. Epub 2016 Jun 22.

12.

Potential Role of Vegetarianism on Nutritional and Cardiovascular Status in Taiwanese Dialysis Patients: A Case-Control Study.

Ou SH, Chen MY, Huang CW, Chen NC, Wu CH, Hsu CY, Chou KJ, Lee PT, Fang HC, Chen CL.

PLoS One. 2016 Jun 13;11(6):e0156297. doi: 10.1371/journal.pone.0156297. eCollection 2016.

13.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.

Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.

14.

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling.

Zhu VW, Upadhyay D, Schrock AB, Gowen K, Ali SM, Ou SH.

Lung Cancer. 2016 Jul;97:48-50. doi: 10.1016/j.lungcan.2016.04.013. Epub 2016 Apr 22.

PMID:
27237027
15.

Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.

Ou SH, Weitz M, Jalas JR, Kelly DF, Wong V, Azada MC, Quines O, Klempner SJ.

Lung Cancer. 2016 Jun;96:15-8. doi: 10.1016/j.lungcan.2016.03.008. Epub 2016 Mar 26.

PMID:
27133743
16.

BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.

Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM.

Cancer Discov. 2016 Jun;6(6):594-600. doi: 10.1158/2159-8290.CD-15-1192. Epub 2016 Apr 5.

17.

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

Li T, LoRusso P, Maitland ML, Ou SH, Bahceci E, Ball HA, Park JW, Yuen G, Tolcher A.

J Hematol Oncol. 2016 Mar 10;9:23. doi: 10.1186/s13045-016-0254-5.

18.

Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing.

Schrock AB, Frampton GM, Herndon D, Greenbowe JR, Wang K, Lipson D, Yelensky R, Chalmers ZR, Chmielecki J, Elvin JA, Wollner M, Dvir A, -Gutman LS, Bordoni R, Peled N, Braiteh F, Raez L, Erlich R, Ou SH, Mohamed M, Ross JS, Stephens PJ, Ali SM, Miller VA.

Clin Cancer Res. 2016 Jul 1;22(13):3281-5. doi: 10.1158/1078-0432.CCR-15-1668. Epub 2016 Mar 1.

19.

Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations.

Reungwetwattana T, Ou SH.

J Thorac Oncol. 2016 Mar;11(3):281-3. doi: 10.1016/j.jtho.2016.01.005. No abstract available.

20.

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).

Drilon A, Li G, Dogan S, Gounder M, Shen R, Arcila M, Wang L, Hyman DM, Hechtman J, Wei G, Cam NR, Christiansen J, Luo D, Maneval EC, Bauer T, Patel M, Liu SV, Ou SH, Farago A, Shaw A, Shoemaker RF, Lim J, Hornby Z, Multani P, Ladanyi M, Berger M, Katabi N, Ghossein R, Ho AL.

Ann Oncol. 2016 May;27(5):920-6. doi: 10.1093/annonc/mdw042. Epub 2016 Feb 15.

21.

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007).

Ou SH, Tang Y, Polli A, Wilner KD, Schnell P.

Cancer Med. 2016 Apr;5(4):617-22. doi: 10.1002/cam4.622. Epub 2016 Jan 28.

22.
23.

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.

Kodityal S, Elvin JA, Squillace R, Agarwal N, Miller VA, Ali SM, Klempner SJ, Ou SH.

Lung Cancer. 2016 Feb;92:19-21. doi: 10.1016/j.lungcan.2015.11.023. Epub 2015 Dec 3.

PMID:
26775591
24.

Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning.

Klempner SJ, Raufi A, Ou SH.

Transl Lung Cancer Res. 2015 Oct;4(5):649-52. doi: 10.3978/j.issn.2218-6751.2015.07.03.

25.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW.

J Clin Oncol. 2016 Mar 1;34(7):661-8. doi: 10.1200/JCO.2015.63.9443. Epub 2015 Nov 23.

PMID:
26598747
26.

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer.

Farago AF, Le LP, Zheng Z, Muzikansky A, Drilon A, Patel M, Bauer TM, Liu SV, Ou SH, Jackman D, Costa DB, Multani PS, Li GG, Hornby Z, Chow-Maneval E, Luo D, Lim JE, Iafrate AJ, Shaw AT.

J Thorac Oncol. 2015 Dec;10(12):1670-4. doi: 10.1097/01.JTO.0000473485.38553.f0.

27.

Identification of BRAF Kinase Domain Duplications Across Multiple Tumor Types and Response to RAF Inhibitor Therapy.

Klempner SJ, Bordoni R, Gowen K, Kaplan H, Stephens PJ, Ou SH, Ali SM.

JAMA Oncol. 2016 Feb;2(2):272-4. doi: 10.1001/jamaoncol.2015.4437. No abstract available.

PMID:
26562024
28.

[Epidemiologic Survey of Blood Donors with HBsAg⁻/HBV DNA⁺ in Chinese Xiamen Area].

Ou SH, Xia JZ, Lin YC, Chen CR.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Oct;23(5):1483-7. doi: 10.7534/j.issn.1009-2137.2015.05.050. Chinese.

PMID:
26524062
29.

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?

Ou SH, Soo RA.

Drug Des Devel Ther. 2015 Oct 15;9:5641-53. doi: 10.2147/DDDT.S52787. eCollection 2015. Review.

30.

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.

Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ.

Lung Cancer. 2016 Jan;91:70-2. doi: 10.1016/j.lungcan.2015.09.006. Epub 2015 Sep 12.

PMID:
26464158
31.

Gastrointestinal malignancies harbor actionable MET exon 14 deletions.

Lee J, Ou SH, Lee JM, Kim HC, Hong M, Kim SY, Jang J, Ahn S, Kang SY, Lee S, Kim ST, Kim B, Choi J, Kim KA, Lee J, Park C, Park SH, Park JO, Lim HY, Kang WK, Park K, Park YS, Kim KM.

Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721.

32.

Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.

Levy BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR.

Oncologist. 2015 Oct;20(10):1175-81. doi: 10.1634/theoncologist.2015-0114. Epub 2015 Sep 1.

33.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG.

Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24.

34.

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.

Lung Cancer. 2015 Sep;89(3):357-9. doi: 10.1016/j.lungcan.2015.06.021. Epub 2015 Jun 29.

PMID:
26187428
35.

Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.

Lee J, Kim HC, Hong JY, Wang K, Kim SY, Jang J, Kim ST, Park JO, Lim HY, Kang WK, Park YS, Lee J, Lee WY, Park YA, Huh JW, Yun SH, Do IG, Kim SH, Balasubramanian S, Stephens PJ, Ross JS, Li GG, Hornby Z, Ali SM, Miller VA, Kim KM, Ou SH.

Oncotarget. 2015 Sep 15;6(27):24320-32.

36.

Syntheses, crystal structures, weak interaction, magnetic and photoluminescent properties of two new organic-inorganic molecular solids with disubstituted benzyl triphenylphosphinium and tetra(isothiocyanate)cobalt(II) anion.

Hu T, Wang BW, Zheng WQ, Zheng XG, Liu QT, Ou SH, Zhan LZ, Zhou JR, Yang LM, Ni CL.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Dec 5;151:490-7. doi: 10.1016/j.saa.2015.06.120. Epub 2015 Jun 30.

PMID:
26160605
37.

Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.

Klempner SJ, Ou SH.

Chin Clin Oncol. 2015 Jun;4(2):20. doi: 10.3978/j.issn.2304-3865.2015.05.03. Review.

38.

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL.

Lancet Oncol. 2015 Jul;16(7):830-8. doi: 10.1016/S1470-2045(15)00026-1. Epub 2015 Jun 4.

PMID:
26051236
39.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, Akimov M, Bufill JA, Lee C, Jentz D, Hoover R, Ou SH, Salgia R, Brennan T, Chalmers ZR, Jaeger S, Huang A, Elvin JA, Erlich R, Fichtenholtz A, Gowen KA, Greenbowe J, Johnson A, Khaira D, McMahon C, Sanford EM, Roels S, White J, Greshock J, Schlegel R, Lipson D, Yelensky R, Morosini D, Ross JS, Collisson E, Peters M, Stephens PJ, Miller VA.

Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.

40.

The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review.

Klempner SJ, Ou SH, Costa DB, VanderLaan PA, Sanford EM, Schrock A, Gay L, Ali SM, Miller VA.

Clin Lung Cancer. 2015 Sep;16(5):334-339.e1. doi: 10.1016/j.cllc.2015.03.004. Epub 2015 Mar 26. Review.

PMID:
25911330
41.

Darkness before dawn, but will the sun always rise?

Ou SH.

Cancer. 2015 Aug 1;121(15):2514-6. doi: 10.1002/cncr.29388. Epub 2015 Apr 17. No abstract available.

42.

Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.

Ou SH, Klempner SJ, Azada MC, Rausei-Mills V, Duma C.

Lung Cancer. 2015 Jun;88(3):355-9. doi: 10.1016/j.lungcan.2015.03.022. Epub 2015 Mar 30.

PMID:
25882777
43.

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Ali SM, Sanford EM, Klempner SJ, Rubinson DA, Wang K, Palma NA, Chmielecki J, Yelensky R, Palmer GA, Morosini D, Lipson D, Catenacci DV, Braiteh F, Erlich R, Stephens PJ, Ross JS, Ou SH, Miller VA.

Oncologist. 2015 May;20(5):499-507. doi: 10.1634/theoncologist.2014-0378. Epub 2015 Apr 16.

44.

Identification of a novel TMEM106B-ROS1 fusion variant in lung adenocarcinoma by comprehensive genomic profiling.

Ou SH, Chalmers ZR, Azada MC, Ross JS, Stephens PJ, Ali SM, Miller VA.

Lung Cancer. 2015 Jun;88(3):352-4. doi: 10.1016/j.lungcan.2015.03.014. Epub 2015 Mar 21.

PMID:
25851827
45.

Multimedia Exercise Training Program Improves Distance Walked, Heart Rate Recovery, and Self-efficacy in Cardiac Surgery Patients.

Wang LW, Ou SH, Tsai CS, Chang YC, Kao CW.

J Cardiovasc Nurs. 2016 Jul-Aug;31(4):343-9. doi: 10.1097/JCN.0000000000000246.

PMID:
25774840
46.

I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib.

Ou SH, Greenbowe J, Khan ZU, Azada MC, Ross JS, Stevens PJ, Ali SM, Miller VA, Gitlitz B.

Lung Cancer. 2015 May;88(2):231-4. doi: 10.1016/j.lungcan.2015.02.005. Epub 2015 Feb 12.

PMID:
25736571
47.

Syntheses, crystal structures, luminescent and magnetic properties of two molecular solids containing naphthylmethylene triphenylphosphinium cations and tetra(isothiocyanate)cobalt(II) dianion.

Cai HT, Liu QT, Ye HQ, Su LJ, Zheng XX, Li JN, Ou SH, Zhou JR, Yang LM, Ni CL.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 May 5;142:239-45. doi: 10.1016/j.saa.2015.01.098. Epub 2015 Feb 9.

PMID:
25703370
48.
49.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, Schnell P, Wilner KD, Wiltshire R, Camidge DR, Crinò L.

J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26.

50.

SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).

Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DR.

J Thorac Oncol. 2015 Feb;10(2):387-91. doi: 10.1097/JTO.0000000000000360.

Supplemental Content

Support Center